argenx SE
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARGX | ROIV | INCY | TGTX | BBIO | SRRK | |
|---|---|---|---|---|---|---|
| Market cap | 51.08B | 24.99B | 22.57B | 8.46B | 12.85B | 5.11B |
| P/E (TTM) | 31.0 | — | 14.2 | 20.1 | — | — |
| Forward P/E | 22.8 | -20.1 | 12.8 | 20.4 | 2,275.1 | -16.6 |
| Price/book | 150.9 | 5.9 | 3.5 | 13.4 | -5.1 | 20.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −0.08% | +118.63% | +33.12% | +61.81% | +16.37% | +23.09% |
| Today | −1.54% | −2.40% | −1.27% | −0.18% | +0.61% | −0.59% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARGX news ›Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Neurogene (NGNE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Neurogene (NGNE) with bullish sentiments. In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a…
What’s next for argenx, Europe’s autoimmune breakthrough?
European Biotechnology: What attracted you to the job at argenx? EB: You worked almost a decade at Roche’s Genentech before joining argenx. What’s the difference between working for a large pharma group and argenx? EB: Can you tell us…
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Shares of Immunovant (IMVT) sold off Thursday as traders treated Argenx’s (ARGX) failed late-stage Sjögren’s trial as a warning for its own experimental drug for the autoimmune disorder. Immunovant (IMVT) fell about 6% to $30.06 in morning…
argenx: The Sjögren's Selloff Looks Overdone
argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate the lost opportunity. Read more on ARGX stock here. - argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears…
argenx drops trial of efgartigimod SC in Sjögren's disease - The Pharma Letter
argenx drops trial of efgartigimod SC in Sjögren's disease The Pharma Letter
Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding…
Argenx falls as Sjögren’s setback offsets celiac drug progress
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more “blockbuster expansion opportunity” for Vyvgart. The success of Vyvgart has propelled Argenx into the ranks of the world’s…
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx SE(NASDAQ:ARGX) on Thursday delivered mixed clinical updates, announcing positive Phase 2 trial results for one experimental pipeline candidate alongside the failure of a Phase 3 study for another therapy. In its first clinical…
argenx drops 10.91% at the open, dwarfing every other loser
As seen on the 24/7 Wall St. homepage on October 8, 2026. argenx is down 10.91% at the open, more than double any other decliner in a 382-stock universe. Palantir leads the gainers at 4.17%, with Big Oil names filling out the rest. argenx…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
theglobeandmail.com5
-
statnews.com3
-
tradingview.com3
-
european-biotechnology.com2
-
marketscreener.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 37 articles, not a forecast.